市场调查报告书
商品编码
1347759
2023-2028 年按治疗、癌症类型(非小细胞肺癌、小细胞肺癌)、分销渠道和地区分類的肺癌治疗市场报告Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2023-2028 |
2022年,全球肺癌治疗市场规模达到272.216亿美元。展望未来,IMARC集团预计到2028年该市场将达到502.33亿美元,2023-2028年復合年增长率(CAGR)为10.90%。由于不健康的生活方式和过度吸烟,肺癌患病率不断上升,个人对早期诊断和治疗重要性的认识不断提高,以及精准医学的进步是推动市场的一些关键因素。
肺癌治疗是指用于控制和治疗肺癌症状的各种治疗方案,包括呼吸短促、胸痛、喘息和咳血。其中包括有助于减少和破坏肺部癌性肿瘤生长的药物和手术。它们还涉及针对癌细胞特定基因突变或改变并刺激免疫系统对抗疾病的疗法。目前,由于吸烟产品消费的增加、污染程度的上升以及不健康的饮食模式,肺癌患病率不断上升,这促进了对有效肺癌治疗方法的需求。
目前,人们对癌症早期诊断和治疗益处的认识不断提高,这是提供良好市场前景的关键因素之一。除此之外,提供个性化治疗选择并改善患者治疗效果的靶向疗法的开发也有利于市场增长。分子测试和基因分析能够识别肺癌细胞中的特定突变和生物标誌物。与此相一致的是,越来越多地使用纳米药物,通过增强疗效和减少副作用来提高抗癌药物向受影响组织的有效递送。此外,越来越多地使用免疫检查点抑製剂(ICIs)作为单一疗法或与其他疗法联合使用,正在创造积极的市场前景。此外,联合疗法(涉及同时使用多种治疗方式)的日益普及正在加强市场增长。除此之外,液体活检的广泛使用正在推动市场的发展,液体活检涉及血液样本中循环肿瘤脱氧核糖核酸(DNA)和其他生物标誌物的分析。液体活检是一种评估肿瘤突变状态和治疗反应的非侵入性方法,从而能够实时监测和调整治疗。此外,製药公司、研究机构和医疗保健提供者之间开发创新疗法和药物的战略合作正在推动市场增长。与此同时,肺癌新型治疗方式、药物输送系统和诊断工具的持续研究和技术进步预计将刺激市场增长。
The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.
IMARC Group provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on therapy, cancer type, and distribution channel.
Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Others
Immunotherapy
Durvalumab
Nivolumab
Atezolizumab
Pembrolizumab
Radiation Therapy
External Beam
Internal Beam
Systemic
Chemotherapy
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for lung cancer therapeutics. Some of the factors driving the North America lung cancer therapeutics market included the increasing prevalence of lung cancer, rising awareness among individuals about the benefits of early diagnosis and treatment, technological advancements in treatment procedures, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.